Form D · Biotechnology
MedGene Therapeutics, Inc.
Silver Spring, MD · CIK 0001789652
Offering snapshot reported Jun 29, 2021 · SEC filing
- Reported sold
- $1.1M Offering amount: $1.1M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 29, 2021 | Initial | $1,100,000 | No comparison | Not reported | SEC filing |
| Oct 28, 2019 | Initial | $51,500 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-404510
Source: Form D, filed Jun 29, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Tae Erk Kim | Director |
| Sean Mc Crohon | Executive |
| Yonghan Park | Director, Executive |
| James Song | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
11800 Georgia Avenue
Silver Spring, MD, 20902
Silver Spring, MD, 20902